(AOF) – Pharnext announces that in accordance with its commitment dated January 17, it has stopped all its operational expenses, the time to complete the additional analyzes of the Premier trial, which is the pivotal Phase III trial of PXT3003, its drug candidate in Charcot-Marie-Tooth disease type 1A (CMT1A).
The biotech confirms having reduced its current consumption as announced and is especially awaiting the upcoming results (before summer 2024) of the Phase III trial currently being carried out in China by its partner Tasly, which acquired the licensing rights for PXT3003 in China in 2017.
If the results of the study conducted in China are negative, Pharnext will analyze these results and draw the necessary conclusions in conjunction with the company’s shareholders. If the results of the study conducted in China are positive, showing the benefit of PXT3003 in a statistically significant manner, Pharnext will continue its dialogue with the FDA and the EMA to agree on a registration process for PXT3003 in CMT1A.
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
